Serotonergic psychedelics are being investigated in the treatment of various disorders and in the improvement of well-being. Evidence suggests that their subjective effects may play a role in long-term behavioral outcomes. The subjective effects are mediated by 5-HT2A receptor agonism, but the 5-HT1A receptor may also play a role in the subjective effects. This study elucidates the effects of 5-HT1A receptor blockade using pindolol pre-treatment on the subjective effects induced by N,N-dimethyltryptamine (DMT).
Methods:
In a double-blind, randomized, placebo-controlled within-subjects design, 12 (10 males, 2 females) experienced hallucinogen-using participants received a sub-hallucinogenic dose of intravenous DMT fumarate, 0.1 mg/kg, after pre-treatment with 30 mg oral racemic pindolol. Subjective effects were measured using the Hallucinogen Rating Scale.
Results:
Pindolol pre-treatment increased DMT-induced subjective effects with a moderate effect size (M = 0.514). Blood pressure and mean arterial pressure also increased with pindolol pre-treatment at 2 minutes following DMT administration, but heart rate was not affected.
Conclusions:
5-HT1A receptor blockade results in a global intensification of DMT-induced subjective effects, suggesting a functional role of 5-HT1A receptor action in the mechanism of psychedelic-induced subjective effects.
AndradeR (2011) Serotonergic regulation of neuronal excitability in the prefrontal cortex. Neuropharmacology61(3): 382–386.
2.
BerendsenHHGBroekkampCLE (1990) Behavioural evidence for functional interactions between 5-HT-receptor subtypes in rats and mice. Br J Pharmacol101(3): 667–673.
3.
BlackburneGMcAlpineRGFabusM, et al. (2025) Complex slow waves in the human brain under 5-MeO-DMT. Cell Rep44(8): 116040.
4.
CanalCEMorganD (2012) Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model. Drug Testing and Analysis4(7–8): 556–576.
5.
CarterOLBurrDCPettigrewJD, et al. (2005) Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors. J Cogn Neurosci17(10): 1497–1508.
6.
DavisAKBarsugliaJPLancelottaR, et al. (2018) The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption. J Psychopharmacol32(7): 779–792.
7.
ErmakovaAODunbarFRuckerJ, et al. (2022) A narrative synthesis of research with 5-MeO-DMT. J Psychopharmacol36(3): 273–294.
8.
FoxMASteinARFrenchHT, et al. (2010) Functional interactions between 5-HT2A and presynaptic 5-HT1A receptor-based responses in mice genetically deficient in the serotonin 5-HT transporter (SERT). Br J Pharmacol159(4): 879–887.
9.
GlatfelterGCClarkAACavalcoNG, et al. (2024) Serotonin 1A receptors modulate serotonin 2A receptor-mediated behavioral effects of 5-methoxy-N,N-dimethyltryptamine analogs in mice. ACS Chem Neurosci15(24): 4458–4477.
10.
GoodwinGMAaronsonSTAlvarezO, et al. (2023) Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. J Affect Disord327: 120–127.
11.
GriffithsRRJohnsonMWCarducciMA, et al. (2016) Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol30(12): 1181–1197.
12.
HalberstadtALKoedoodLPowellSB, et al. (2011) Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice. J Psychopharmacol25(11): 1548–1561.
13.
JardriRHugdahlKHughesM, et al. (2016) Are hallucinations due to an imbalance between excitatory and inhibitory influences on the brain?Schizophr Bull42(5): 1124–1134.
14.
KelmendiBKayeAPPittengerC, et al. (2022) Psychedelics. Current Biol32(2): R63–R67.
15.
KometerMSchmidtABachmannR, et al. (2012) Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors. Biol Psychiatry72(11): 898–906.
16.
KrebsKMGeyerMA (1994) Cross-tolerance studies of serotonin receptors involved in behavioral effects of LSD in rats. Psychopharmacology (Berl)113(3–4): 429–437.
17.
Krebs-ThomsonKGeyerMA (1998) Evidence for a functional interaction between 5-HT1A and 5-HT2 receptors in rats. Psychopharmacology (Berl)140(1): 69–74.
18.
López-GiménezJFGonzález-MaesoJ (2018) Hallucinogens and serotonin 5-HT(2A) receptor-mediated signaling pathways. Curr Top Behav Neurosci36: 45–73.
19.
LuJTjiaMMullenB, et al. (2021) An analog of psychedelics restores functional neural circuits disrupted by unpredictable stress. Molecular Psychiatry26(11): 6237–6252.
20.
MadsenMKFisherPMBurmesterD, et al. (2019) Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology44(7): 1328–1334.
21.
McCallRBPatelBNHarrisLT (1987) Effects of serotonin1 and serotonin2 receptor agonists and antagonists on blood pressure, heart rate and sympathetic nerve activity. Journal of Pharmacology and Experimental Therapeutics242(3): 1041–1048.
22.
MetastasioAPreveteEVenturiniS, et al. (2025) The phenomenology of psilocybin: Transformative insights for research and clinical practice. Frontiers in Psychology16: 1455902.
23.
PalchaudhuriMFlüggeG (2005) 5-HT1A receptor expression in pyramidal neurons of cortical and limbic brain regions. Cell Tissue Res321(2): 159–172.
24.
PokornyTPrellerKHKraehenmannR, et al. (2016) Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience. Eur Neuropsychopharmacol26(4): 756–766.
25.
R Core Team (2025) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Available at: https://www.R-project.org/
26.
RaisonCLJainRPennAD, et al. (2022) Effects of naturalistic psychedelic use on depression, anxiety, and well-being: Associations with patterns of use, reported harms, and transformative mental states. Front Psychiatry13: 831092.
27.
RazakarivonyONewman-TancrediAZimmerL (2021) Towards in vivo imaging of functionally active 5-HT(1A) receptors in schizophrenia: Concepts and challenges. Transl Psychiatry11(1): 22.
28.
ReissigCJEcklerJRRabinRA, et al. (2005) The 5-HT1A receptor and the stimulus effects of LSD in the rat. Psychopharmacology (Berl)182(2): 197–204.
29.
RosemanLNuttDJCarhart-HarrisRL (2017) Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front Pharmacol8: 974.
30.
SchmitzDGloveliTEmpsonRM, et al. (1998) Serotonin reduces synaptic excitation in the superficial medial entorhinal cortex of the rat via a presynaptic mechanism. J Physiol508: 119–129.
31.
StrassmanRJ (1996) Human psychopharmacology of N,N-dimethyltryptamine. Behav Brain Res73(1–2): 121–124.
32.
StrassmanRJQuallsCR (1994) Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects. Arch Gen Psychiatry51(2): 85–97.
33.
StrassmanRJQuallsCRUhlenhuthEH, et al. (1994) Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry51(2): 98–108.
34.
The MathWorks, Inc. (2024) MATLAB version: R2024b. Natick, Massachusetts, United States: The MathWorks, Inc. Available at: https://www.mathworks.com
35.
TimmermannCSandersJWReydelletD, et al. (2025) Exploring 5-MeO-DMT as a pharmacological model for deconstructed consciousness. Neuroscience of Consciousness2025(1): niaf007.
36.
VollenweiderFXVollenweider-ScherpenhuyzenMFBäblerA, et al. (1998) Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport9(17): 3897–3902.
37.
WeberETAndradeR (2010) Htr2a gene and 5-HT(2A) receptor expression in the cerebral cortex studied using genetically modified mice. Front Neurosci4: 36.
38.
WinterJCRiceKCAmorosiDJ, et al. (2007) Psilocybin-induced stimulus control in the rat. Pharmacol Biochem Behavior87(4): 472–480.
39.
YadenDBGoldySPWeissB, et al. (2024) Clinically relevant acute subjective effects of psychedelics beyond mystical experience. Nat Rev Psychol3(9): 606–621.
40.
YadenDBGriffithsRR (2021) The subjective effects of psychedelics are necessary for their enduring therapeutic effects. ACS Pharmacol Transl Sci4(2): 568–572.
41.
ZahidZ (2025) 5-HT1A receptor blockade potentiates the subjective effects of DMT. Available at: https://osf.io/vpagm (accessed 26 November 2025).
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
